MiMedx Group, Inc. (NASDAQ:MDXG) Receives $12.00 Average Target Price from Brokerages

MiMedx Group, Inc. (NASDAQ:MDXG) has earned an average rating of “Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Several analysts have recently weighed in on the stock. Craig Hallum decreased their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 price objective on shares of MiMedx Group in a research note on Thursday, August 1st. Finally, StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Monday, August 5th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. AJOVista LLC acquired a new position in MiMedx Group in the fourth quarter valued at approximately $25,000. Headlands Technologies LLC acquired a new position in shares of MiMedx Group in the 1st quarter valued at $27,000. Isthmus Partners LLC boosted its position in shares of MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after purchasing an additional 91,714 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of MiMedx Group during the second quarter worth $40,000. Finally, Quest Partners LLC bought a new stake in MiMedx Group in the second quarter valued at about $81,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Stock Performance

Shares of MDXG opened at $6.84 on Thursday. The company has a quick ratio of 3.22, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. MiMedx Group has a 12 month low of $5.57 and a 12 month high of $9.27. The company’s fifty day moving average is $6.84 and its 200-day moving average is $7.20. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of 15.55 and a beta of 1.98.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. The company had revenue of $87.21 million for the quarter, compared to the consensus estimate of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. Equities analysts expect that MiMedx Group will post 0.26 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.